id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2006-E-0197-0007,FDA,FDA-2006-E-0197,Determination of Regulatory Review Periods for Purposes of Patent Extension; SPRYCEL--New Drug Applications 2 1-986 and 22-072,Notice,General Notice,2007-05-25T04:00:00Z,2007,5,2007-05-25T04:00:00Z,,2025-12-19T00:33:26Z,E7-10089,0,0,0900006480450efc
FDA-2006-E-0197-0006,FDA,FDA-2006-E-0197,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2007-05-17T04:00:00Z,2007,5,,,2025-12-19T00:29:59Z,,0,0,0900006480450efb
FDA-2006-E-0197-0005,FDA,FDA-2006-E-0197,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2007-03-06T05:00:00Z,2007,3,,,2025-12-19T00:14:46Z,,0,0,0900006480450efa
FDA-2006-E-0197-0004,FDA,FDA-2006-E-0197,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2007-01-26T05:00:00Z,2007,1,,,2025-12-19T00:08:24Z,,0,0,0900006480450ef9
FDA-2006-E-0197-0003,FDA,FDA-2006-E-0197,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2007-01-26T05:00:00Z,2007,1,,,2025-12-19T00:06:08Z,,0,0,0900006480450ef8